Skin cancer vaccine shows complete tumor regression in 50% of mice

A

cross-disciplinary team of Harvard scientists, engineers, and clinicians announced today that they have begun a Phase I clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer.

The technology was initially designed to target cancerous cells in skin, but might have application to other cancers. In the preclinical study reported in Science Translational Medicine, 50 percent of mice treated with two doses of the vaccine — mice that would have otherwise died from melanoma within about 25 days — showed complete tumor regression.

The technology was initially designed to target cancerous cells in skin, but might have application to other cancers.

The goal of the Phase I study, which is expected to conclude in 2015, is to assess the safety of the vaccine in humans.

VIDEO HERE Cancer vaccine begins Phase I clinical trials | Harvard Gazette.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s